DE69203874D1 - Verwendung von (omega-(4-(2-Pyrimidinyl)-1-piperazinyl)-alkyl)1H-Azolderivate für die Herstellung von Heilmitteln zur Behandlung von Störungen kognitiver Funktionen. - Google Patents

Verwendung von (omega-(4-(2-Pyrimidinyl)-1-piperazinyl)-alkyl)1H-Azolderivate für die Herstellung von Heilmitteln zur Behandlung von Störungen kognitiver Funktionen.

Info

Publication number
DE69203874D1
DE69203874D1 DE69203874T DE69203874T DE69203874D1 DE 69203874 D1 DE69203874 D1 DE 69203874D1 DE 69203874 T DE69203874 T DE 69203874T DE 69203874 T DE69203874 T DE 69203874T DE 69203874 D1 DE69203874 D1 DE 69203874D1
Authority
DE
Germany
Prior art keywords
radical
alkyl
disorders
manufacture
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69203874T
Other languages
English (en)
Other versions
DE69203874T2 (de
Inventor
Jordi Frigola Constansa
Juan Pares Corominas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE69203874D1 publication Critical patent/DE69203874D1/de
Application granted granted Critical
Publication of DE69203874T2 publication Critical patent/DE69203874T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
DE69203874T 1991-01-25 1992-01-22 Verwendung von (omega-(4-(2-Pyrimidinyl)-1-piperazinyl)-alkyl)1H-Azolderivate für die Herstellung von Heilmitteln zur Behandlung von Störungen kognitiver Funktionen. Expired - Fee Related DE69203874T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9100861A FR2671972B1 (fr) 1991-01-25 1991-01-25 Utilisation de derives 1-h-azole-(omega-(4-(2-pyrimidinyl)-1-piperazinyl)-alkyl) pour la preparation de medicaments destines au traitement des troubles des fonctions cognitives.

Publications (2)

Publication Number Publication Date
DE69203874D1 true DE69203874D1 (de) 1995-09-14
DE69203874T2 DE69203874T2 (de) 1995-12-07

Family

ID=9409058

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69203874T Expired - Fee Related DE69203874T2 (de) 1991-01-25 1992-01-22 Verwendung von (omega-(4-(2-Pyrimidinyl)-1-piperazinyl)-alkyl)1H-Azolderivate für die Herstellung von Heilmitteln zur Behandlung von Störungen kognitiver Funktionen.

Country Status (16)

Country Link
US (1) US5182281A (de)
EP (1) EP0497658B1 (de)
JP (1) JPH07121865B2 (de)
KR (1) KR970001655B1 (de)
AT (1) ATE126227T1 (de)
AU (1) AU646137B2 (de)
CA (1) CA2059984A1 (de)
DE (1) DE69203874T2 (de)
DK (1) DK0497658T3 (de)
ES (1) ES2125207B1 (de)
FR (1) FR2671972B1 (de)
GR (1) GR3017648T3 (de)
HU (1) HU214319B (de)
NO (1) NO179695C (de)
RU (1) RU2078568C1 (de)
ZA (1) ZA92504B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681956A (en) * 1990-12-28 1997-10-28 Neurogen Corporation 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands
US5712392A (en) * 1990-12-28 1998-01-27 Neurogen Corporation Certain 4-piperidine- and piperazinoalkyl-2-phenyl imidazole derivatives; dopamine receptor subtype specific ligands
FR2701260B1 (fr) * 1993-02-05 1995-05-05 Esteve Labor Dr Dérivés de 2-[4-(4-azolylbutyl)-1-pipérazinyl]-5-hydroxypyrimidine, leur préparation et leur application en tant que médicaments.
FR2705098B1 (fr) * 1993-05-10 1995-08-04 Esteve Labor Dr Procédé de préparation de 2-{4-[4-(chloro-1-pyrazolyl)butyl]1-pipérazinyl}pyrimidine (Lesopitron) .
GB9408084D0 (en) * 1994-04-23 1994-06-15 Boots Co Plc Medical treatment
FR2723091B1 (fr) * 1994-07-29 1996-11-08 Esteve Labor Dr Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles
US6355659B1 (en) 1994-07-29 2002-03-12 Laboratorios Del Dr. Esteve, S.A. 4-(4-Chlorophenyl)-1236-tetrahydro-1(1H-124-triazol-1-yl)butty)pyrideine and salts thereof; pharmaceutical compositions and method of treating psychoses utilizing same
ES2117934B1 (es) * 1994-07-29 1999-04-01 Esteve Labor Dr Tetrahidropiridinas (0 4-hidroxipiperidinas) alquilazoles.
ES2099031B1 (es) * 1995-05-31 1997-12-01 Esteve Labor Dr Nuevos polimorfos de diclorhidrato de lesopitron y sus formas hidratadas, procedimientos de preparacion y composiciones que los contienen.
US6166205A (en) * 1998-09-02 2000-12-26 Neurogen Corporation 2-Aryl-4-(1-[4-heteroaryl]piperazin-1-yl)methylimidazoles: dopamine . D.sub4 receptor subtype ligands
US7763074B2 (en) 2004-10-20 2010-07-27 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for posterior dynamic stabilization of the spine
US8123807B2 (en) 2004-10-20 2012-02-28 Vertiflex, Inc. Systems and methods for posterior dynamic stabilization of the spine
US8123782B2 (en) * 2004-10-20 2012-02-28 Vertiflex, Inc. Interspinous spacer
US8167944B2 (en) 2004-10-20 2012-05-01 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for posterior dynamic stabilization of the spine
US8012207B2 (en) * 2004-10-20 2011-09-06 Vertiflex, Inc. Systems and methods for posterior dynamic stabilization of the spine
US9023084B2 (en) * 2004-10-20 2015-05-05 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for stabilizing the motion or adjusting the position of the spine
US8409282B2 (en) 2004-10-20 2013-04-02 Vertiflex, Inc. Systems and methods for posterior dynamic stabilization of the spine
US8425559B2 (en) 2004-10-20 2013-04-23 Vertiflex, Inc. Systems and methods for posterior dynamic stabilization of the spine
US8317864B2 (en) 2004-10-20 2012-11-27 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for posterior dynamic stabilization of the spine
US8613747B2 (en) * 2004-10-20 2013-12-24 Vertiflex, Inc. Spacer insertion instrument
US8152837B2 (en) 2004-10-20 2012-04-10 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for posterior dynamic stabilization of the spine
US8273108B2 (en) * 2004-10-20 2012-09-25 Vertiflex, Inc. Interspinous spacer
US9119680B2 (en) 2004-10-20 2015-09-01 Vertiflex, Inc. Interspinous spacer
US8945183B2 (en) * 2004-10-20 2015-02-03 Vertiflex, Inc. Interspinous process spacer instrument system with deployment indicator
US9161783B2 (en) 2004-10-20 2015-10-20 Vertiflex, Inc. Interspinous spacer
US8128662B2 (en) 2004-10-20 2012-03-06 Vertiflex, Inc. Minimally invasive tooling for delivery of interspinous spacer
US8277488B2 (en) * 2004-10-20 2012-10-02 Vertiflex, Inc. Interspinous spacer
WO2009086010A2 (en) 2004-12-06 2009-07-09 Vertiflex, Inc. Spacer insertion instrument
US8845726B2 (en) 2006-10-18 2014-09-30 Vertiflex, Inc. Dilator
CA2684461C (en) 2007-04-16 2015-06-30 Vertiflex Inc. Interspinous spacer
EP2244670B1 (de) 2008-01-15 2017-09-13 Vertiflex, Inc. Interspinöses abstandsglied
US8740948B2 (en) 2009-12-15 2014-06-03 Vertiflex, Inc. Spinal spacer for cervical and other vertebra, and associated systems and methods
US9675303B2 (en) 2013-03-15 2017-06-13 Vertiflex, Inc. Visualization systems, instruments and methods of using the same in spinal decompression procedures
AU2015256024B2 (en) 2014-05-07 2020-03-05 Vertiflex, Inc. Spinal nerve decompression systems, dilation systems, and methods of using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2642759B1 (fr) * 1989-02-09 1991-05-17 Laboratorios Esteve Sa Derives de pyrimidyl-piperazinyl-alkyl azoles avec activite anxiolytique et/ou tranquillisante
FR2654621B1 (fr) * 1989-11-22 1994-09-23 Esteve Labor Dr Inhibition du syndrome d'abstinence.

Also Published As

Publication number Publication date
HU9200232D0 (en) 1992-04-28
US5182281A (en) 1993-01-26
KR970001655B1 (ko) 1997-02-13
HU214319B (hu) 1998-03-02
GR3017648T3 (en) 1996-01-31
FR2671972A1 (fr) 1992-07-31
JPH04312529A (ja) 1992-11-04
EP0497658B1 (de) 1995-08-09
ES2125207B1 (es) 1999-01-01
ZA92504B (en) 1992-10-28
HUT60433A (en) 1992-09-28
NO920342D0 (no) 1992-01-24
ATE126227T1 (de) 1995-08-15
CA2059984A1 (fr) 1992-07-26
DE69203874T2 (de) 1995-12-07
AU1044592A (en) 1992-07-30
NO920342L (no) 1992-07-27
RU2078568C1 (ru) 1997-05-10
AU646137B2 (en) 1994-02-10
KR920014472A (ko) 1992-08-25
NO179695C (no) 1996-12-04
FR2671972B1 (fr) 1995-03-03
DK0497658T3 (da) 1995-10-02
EP0497658A1 (de) 1992-08-05
NO179695B (no) 1996-08-26
JPH07121865B2 (ja) 1995-12-25

Similar Documents

Publication Publication Date Title
DE69203874T2 (de) Verwendung von (omega-(4-(2-Pyrimidinyl)-1-piperazinyl)-alkyl)1H-Azolderivate für die Herstellung von Heilmitteln zur Behandlung von Störungen kognitiver Funktionen.
HUT68357A (en) Heterocyclic-cyclic-amine derivatives, pharmaceutical compositions containing them and process for their production
ES2100129B1 (es) Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion.
ATE170530T1 (de) Thiazolidinderivate, ihre herstellung und medikamente, die sie enthalten
DE69216293D1 (de) 1,4-Disubstituierte Piperidinderivate, ihre Herstellung und therapeutische Verwendung
ATE161723T1 (de) Arzneimittel zur verwendung bei der behandlung von parkinsonismus
ATE112166T1 (de) Verwendung von 1-(3-(dimethylamino)propyl>-1- phenylphthalenen zur behandlung zerebrovaskulärer störungen.
ATE73445T1 (de) 1,2,5,6-tetrahydropyridinoxim-derivate, verfahren zu deren herstellung, deren verwendung als arzneimittel und diese enthaltende zusammensetzungen.
ATE73785T1 (de) 5-(3-alkyl-5-tert.butyl-4-hydroxyphenyl)-2-amin - 6h-1,3,4-thiadiazine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung.
ATE100092T1 (de) 4-methyl-5(2-(4-phenyl-1-piperazinyl)-ethyl>thiazolderivate,ihre herstellung und zusammenstellungen, die sie enthalten.
ATE71938T1 (de) 1,2,5,6-tetrahydropyridin-3-carboxaldehydoximderivate, verfahren zu deren herstellung, deren verwendung als arzneimittel und diese enthaltende zusammensetzungen.
DE68902627D1 (de) Verwendung von chromanderivaten zur herstellung eines medikamentes zur behandlung von depressiven zustaenden.
ATE168697T1 (de) Pyrrolidinderivate zur behandlung von cck und gastrin-abhängigen erkrankungen
DE3860117D1 (de) 2,3-dihydro-3-phenyl-benzofuran-2-on-acetamidderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
IT1261958B (it) 2-(sostituite immino)-tiazolidine e procedimento per la loro preparazione e loro impiego quali antianginose e/o analgesiche
RU93004471A (ru) Пиперидилокси- и хинуклидинилокси-изоксазоловые производные и фармацевтическая композиция на их основе

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee